Drugs / insulin isophane
insulin isophane
Trials 0
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT00000620 Background | Sep 1999 → Jun 2009 | atherosclerosis, coronary artery disorder, hyperlipoproteinemia, hypertensive disorder +1 | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT01963728 Comparator | Nov 2013 → Apr 2015 | diabetes mellitus | Inova Health Care Services | Terminated | No outcome recorded |
| Phase 4 | NCT00346996 Comparator | May 2007 → Nov 2011 | type 1 diabetes mellitus | Lise Tarnow | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | insulin isophane | “Because of this pattern, transplant patients may respond better to morning insulin isophane (intermediate acting) than to long-acting insulin glargine preparations.” NCT01963728 ↗ |
| Known as | human NPH | “human NPH (Novolin N)” NCT00000620 ↗ |
| Known as | human NPH (Novolin N) | “human NPH (Novolin N)” NCT00000620 ↗ |
| Known as | isophane insulin | “Our trial is designed to compare morning NPH insulin (isophane insulin) with conventional therapy of basal glargine insulin on both continuous blood glucose levels and...” NCT01963728 ↗ |
| Known as | NPH insulin | “Our trial is designed to compare morning NPH insulin (isophane insulin) with conventional therapy of basal glargine insulin on both continuous blood glucose levels and...” NCT01963728 ↗ |
| Route | Subcutaneous | “for subcutaneous injection” NCT00346996 ↗ |